Home

Applications

APPLICATIONS OVERVIEW
DRUG DISCOVERY
ADME-Tox
Biochemical Assays
Cell-based Assays
HTS and Secondary Screening
Microsampling
Protein Crystallography
RNAi
Sample Management
CANCER RESEARCH
Personalized Medicine
Functional Screening / DSRT
RNAi
Sequencing
Single-cell Genomics
GENOMIC RESEARCH
Gene Expression
Genotyping
Microbiome
qPCR
Sequencing
Single-cell Genomics
Synthetic Biology

Products

LIQUID HANDLING
LIQUID HANDLERS OVERVIEW
Echo® 525 Liquid Handler
Echo® 555 Liquid Handler
Echo® 550 Liquid Handler
Echo® 520 Liquid Handler
AUTOMATION
AUTOMATION OVERVIEW
Access™ Laboratory Workstation
Tempo™ Automation Control Software
SOFTWARE APPLICATIONS
SOFTWARE OVERVIEW
Echo® Array Maker
Echo® Cherry Pick
Echo® Combination Screen
Echo® Compliance Manager
Echo® Dose-Response
Echo® Plate Audit
Echo® Plate Reformat
CONSUMABLES
CONSUMABLES OVERVIEW
Echo® Qualified Microplates
Labcyte® Assay Microplates
MicroClime® Environmental Lid
Echo® Qualified Reservoir

Technology

Echo® Acoustic Liquid Handling
Dynamic Fluid Analysis™
Acoustic Mass Spectrometry
Direct Dilution

News / Events

Labcyte BLOG
Upcoming Events
Press Releases
Labcyte in the News
Labcyte Community

Resources

JALA Special Issue
Publications
Articles and Other Media
Application Notes
Posters
Webinars
Videos
Customer Profiles
Core Labs

Support

Brochures
Web Documentation*
User Guides*
Quick Start Guides*
Specification Sheets
Site Prep Guides
Service and Maintenance
Request Information

Company

About Us
Echo® Acoustic Technology
Leadership Team
Meet Labcyte
Careers
Contact and Location
Privacy Policy

Labcyte BLOG

Acoustic Liquid Handling Is Making Personalized Medicine a Reality
MONDAY, APRIL 25, 2016
linkedin twitter facebook |  42Shares

Labcyte Senior Research Fellow Joe Olechno has a new article in Personalized Medicine in Oncology that offers an informative view of how the Echo® Liquid Handler based on acoustic droplet ejection technology has been instrumental in recent efforts using ex vivo cell assays to inform individualized treatment decisions.


In “The Rebirth of Ex Vivo Cell Screening for Clinical Use,” Dr. Olechno discusses how the miniaturization of reactions with acoustic liquid handling allows scientists to test large numbers of drugs and drug combinations to measure their effect directly on cancer cells taken from a patient. It’s a marked improvement over years of testing cell lines that demonstrate genotypic and phenotypic drift from their original state.


Dr. Olechno took the opportunity to showcase some Labcyte customers turning out truly impressive data using this approach. At the Institute for Molecular Medicine (FIMM) at the University of Helsinki, for instance, scientists use acoustic liquid handling as part of a system that “can assess the sensitivity and resistance of an individual patient’s tumors to hundreds of drugs and drug combinations in a matter of days,” he reports. “With this system, patients in whom several rounds of therapy have failed have received new therapy that led to remission.” FIMM also uses this information to generate a drug sensitivity score, which helps physicians tailor chemo treatments specifically for each patient.


Another example comes from Vivia Biotech , a Spanish diagnostic lab that develops cell screening assays that accurately reflect the tumor microenvironment. “Vivia has profiled samples from patients with acute myeloid leukemia using an automated flow cytometry technique to show how examination of individual tumors can help guide combination therapy,” Dr. Olechno writes.


Both of these organizations demonstrate the remarkable potential for ex vivo cell screening in personalizing treatment for patients, from choosing the best drug or combination of drugs to determining the most effective dosage. “Looking first at an ex vivo assay will both prevent ineffective rounds of chemotherapy and lead to faster cures,” he writes.


We’re very proud that acoustic liquid handling is helping scientists achieve this incredible vision for better healthcare.